Human immunodeficiency virus type 1 drug susceptibility during zidovudine (AZT) monotherapy compared with AZT plus 2',3'-dideoxyinosine or AZT plus 2',3'-dideoxycytidine combination therapy. The protocol 34,225-02 Collaborative Group.

Source:http://linkedlifedata.com/resource/pubmed/id/8709213

Download in:

View as

General Info

PMID
8709213